- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp stock price live, this page displays NASDAQ PDSB stock exchange data. View the PDSB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the PDS Biotechnology Corp real time stock price chart below.
What Is the PDS Biotechnology Corp Stock Price Today?
The PDS Biotechnology Corp stock price today is 0.219.
What Is the Stock Symbol for PDS Biotechnology Corp?
The stock symbol for PDS Biotechnology Corp is "PDSB."
What Stock Exchange Does PDS Biotechnology Corp Trade On?
PDS Biotechnology Corp is listed and trades on the NASDAQ stock exchange.
Is PDS Biotechnology Corp a Good Stock to Buy?
Determining whether PDS Biotechnology Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PDSB quote. (ISIN: US70465T1079)
What Is the PDS Biotechnology Corp Stock Price Today?
The PDS Biotechnology Corp stock price today is 0.219.
What Is the Stock Symbol for PDS Biotechnology Corp?
The stock symbol for PDS Biotechnology Corp is "PDSB."
What Stock Exchange Does PDS Biotechnology Corp Trade On?
PDS Biotechnology Corp is listed and trades on the NASDAQ stock exchange.
Is PDS Biotechnology Corp a Good Stock to Buy?
Determining whether PDS Biotechnology Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PDSB quote. (ISIN: US70465T1079)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.208
0.236
52 wk Range
0.195
1.550
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.2080.236
52 wk Range
0.1951.550
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PDSB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
5.750
Upside
+2,525.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with high price volatility
Form 8K PDS Biotechnology Corp For: 13 August- Investing.com
- Form 8K PDS Biotechnology Corp For: 19 August
- Investing.com
- Form 8K PDS Biotechnology Corp For: 11 August
- Investing.com
- Form 8K PDS Biotechnology Corp For: 19 August
- Investing.com
Form 8K PDS Biotechnology Corp For: 14 August- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.750
(+2,525.57% Upside)
PDS Biotechnology Corp Earnings Call Summary for Q1/2026
- PDS Biotechnology Q1 2026 EPS of -$0.13 beat analyst expectations of -$0.15 by 13.33%; stock rose 6.36% premarket to $1.17
- Net loss improved 14.1% YoY to $7.3M; R&D expenses down 39.7% to $3.5M, G&A expenses decreased 6.1% to $3.1M
- Company maintains strong cash position of $21.7M as of March 31, 2026, supporting ongoing clinical programs
- Strategic amendments to VERSATILE-003 trial expected to accelerate approval processes and shorten trial duration
- Management projects continued EPS losses but emphasizes operational efficiency gains and trial streamlining to enhance shareholder value
Last Updated: 2026-05-13, 08:44 a/m
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-0.18 / -0.13
Revenue / Forecast
-- / --
Compare PDSB to Peers and Sector
Metrics to compare | PDSB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPDSBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −3.3x | −0.4x | |
PEG Ratio | −0.01 | 0.03 | 0.00 | |
Price/Book | −3.4x | 1.6x | 2.6x | |
Price / LTM Sales | - | 79.9x | 3.1x | |
Upside (Analyst Target) | - | 143.9% | 48.9% | |
Fair Value Upside | Unlock | −1.9% | 6.2% | Unlock |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the PDS Biotech (PDSB) Stock Price Today?
The PDS Biotech stock price today is 0.219 USD.
What Stock Exchange Does PDS Biotech Trade On?
PDS Biotech is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for PDS Biotech?
The stock symbol for PDS Biotech is "PDSB."
What Is the PDS Biotech Market Cap?
As of today, PDS Biotech market cap is 12.230M USD.
What Is PDS Biotech's Earnings Per Share (TTM)?
The PDS Biotech EPS (TTM) is -0.640.
When Is the Next PDS Biotech Earnings Date?
PDS Biotech will release its next earnings report on Nov 12, 2026.
From a Technical Analysis Perspective, Is PDSB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has PDS Biotech Stock Split?
PDS Biotech has split 1 times.
How Many Employees Does PDS Biotech Have?
PDS Biotech has 21 employees.
What is the current trading status of PDS Biotech (PDSB)?
As of Aug 23, 2026, PDS Biotech (PDSB) is trading at a price of 0.219 USD, with a previous close of 0.209 USD. The stock has fluctuated within a day range of 0.208 USD to 0.236 USD, while its 52-week range spans from 0.195 USD to 1.550 USD.
What Is PDS Biotech (PDSB) Price Target According to Analysts?
The average 12-month price target for PDS Biotech is 5.750 USD, with a high estimate of 7 USD and a low estimate of 4.5 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,525.57% Upside potential.
What Is the PDSB Premarket Price?
PDSB's last pre-market stock price is 0.210 USD. The pre-market share volume is 19,040.000, and the stock has decreased by 0.001, or 0.480%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.